Table 2.
Assessment of pain intensity, cognition, disability, and insomnia between rehabilitation and ILIB treatment groups
| Variable | Pre-treatment | Post-treatment | 1 month post-treatment | |||
|---|---|---|---|---|---|---|
| Rehab | ILIB | Rehab | ILIB | Rehab | ILIB | |
| VAS for pain (mean ± SD) | 4.89 (2.55) | 5.07 (1.59) | 3.33 (2.78) | 2.63 (1.74)b | 3.61 (2.69) | 3.30 (2.32)c |
| MOCA (mean ± SD) | 24.56 (5.34) | 27.13 (2.03) | 25.11 (5.09) | 28.33 (1.18)b | 25.67 (5.12) | 28.60 (1.68)c |
| MIDAS (mean ± SD) | 74.67 (74.17) | 30.40 (33.29) | 62.33 (56.04) | 32.2 (50.82) | 30.67 (31.85) | 10.13 (18.62)c |
| AIS (mean ± SD) | 8.67 (5.87) | 8.06 (4.42) | 6.78 (7.03) | 3.60 (2.85)b | 6.33 (4.44) | 3.80 (4.16)a,c |
ILIB, intravascular laser irradiation of blood; VAS, Visual Analog Scale; MOCA, Montreal Cognitive Assessment; MIDAS, Migraine Disability Assessment; AIS, Athens Insomnia Scale
aA p-value of < 0.05 was significant in the experiment group of 1 month post-ILIB compared to the control group of 1 month post-ILIB
bA p-value of < 0.05 was significant in the experiment group of Psot-ILIB compared to the experiment group of Pre-ILIB
cA p-value of < 0.05 was significant in the experiment group of 1 month psot-ILIB compared to the experiment group of Pre-ILIB